Streamlining the Switch from IV to SubQ

Intravenous (IV) insulin infusion is a standard protocol for treating critically ill, hospitalized patients with hyperglycemia. However, once glucose levels stabilize, SubQ-and-IV-Popout-01-21-16patients may be transitioned to subcutaneous insulin injections (injections directly below the outer skin layer).

Change is rarely easy. The transition from IV to subcutaneous dosing involves many variables and can be tricky to achieve without a few bumps along the way. While some hospitals follow standard transition protocols, these protocols are not patient-specific and can push the patient into a hyperglycemic, hypoglycemic swing.

Today, EndoTool provides an easier way for this difficult practice. Through a simple guided process, it supports automated protocols for monitoring and dosing during the transition to subcutaneous dosing and the system’s SubQ tool.

Initially, EndoTool notifies clinicians with a “Stable Advisory” message when a patient has maintained consistent glucose levels for the requisite time period and is ready for transition.

EndoTool is configurable to set an overlap of IV and subcutaneous dosing, which is typically between one and four hours. With this pre-programmed, the clinician will then be prompted to stop the IV drip when appropriate.

Afterwards, EndoTool SubQ takes over completely, ensuring safe personalized and predictive dosing. The platform leverages EndoTool’s personalized IV insulin dosing calculations to further refine dosing if needed, reducing the risk of hypoglycemia. When indicated, it also provides carbohydrate recommendations to maintain a healthy glycemic index.

The switch is easy when it’s personal!